Medical treatment of idiopathic menorrhagia;Hémorragies utérines fonctionnelles ou ménorragies idiopathiques. Traitement médical: Modalités, efficacité, complications

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 37, Issue 8 SUPPL. 1, 2008, Pages

  Graesslin, O ^a   Derniaux, E ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Antifibrinolytics; Dysfunctinal uterine bleeding; Levonorgestrel intra uterine device; Medical treatment; NSAIDs

Indexed keywords

ANTIFIBRINOLYTIC AGENT; DANAZOL; ESTROGEN; ETAMSYLATE; GESTAGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRANEXAMIC ACID; CONTRACEPTIVE AGENT;

ACNE; ASTHENIA; ASTHMA; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DYSPEPSIA; EDEMA; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; HEADACHE; HIRSUTISM; HUMAN; HYSTERECTOMY; IDIOPATHIC DISEASE; MASTALGIA; MENORRHAGIA; MENSTRUAL CYCLE; NAUSEA; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PREMENSTRUAL SYNDROME; REVIEW; SEBORRHEA; SPOTTING; TREATMENT INDICATION; UTERUS BLEEDING; ARTICLE; DRUG EFFECT; FEMALE; UTERUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; CONTRACEPTIVE AGENTS, FEMALE; ESTROGENS; FEMALE; HUMANS; LEVONORGESTREL; MENORRHAGIA; PROGESTINS; UTERINE HEMORRHAGE; UTERUS;

EID: 69849099008     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0368-2315(08)74779-3     Document Type: Article

References (115)

1. Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev 2006 Feb;27:17-46.
2. Molenda HA, Kilts CP, Allen RL, Tetel MJ. Nuclear receptor coactivator function in reproductive physiology and behavior. Biol Reprod 2003 Nov;69:1449-1457
3. Saunders P, Critchley H. Estrogen receptor subtypes in the female reproductive tract. Reprod Med Rev 2002;10:149-164 (Pubitemid 36227816)
4. Milne SA, Jabbour HN. Prostaglandin (PG) F(2alpha) receptor expression and signaling in human endometrium: role of PGF(2alpha) in epithelial cell proliferation. J Clin Endocrinol Metab 2003 Apr;88:1825-1832.
5. Ylikorkala O, Makila UM. Prostacyclin and thromboxane in gynecology and obstetrics. Am J Obstet Gynecol 1985 Jun 1;152:318-329
6. Gleeson NC. Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. Am J Obstet Gynecol 1994 Jul;171:178-183
7. Salamonsen LA, Zhang J, Hampton A, Lathbury L. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 2000 Aug;15 Suppl 3:112-119
8. Nayak NR, Critchley HO, Slayden OD, Menrad A, Chwalisz K, Baird DT, et al. Progesterone withdrawal up-regulates vascular endothelial growth factor receptor type 2 in the superficial zone stroma of the human and macaque endometrium: potential relevance to menstruation. J Clin Endocrinol Metab 2000 Sep;85:3442-3452 (Pubitemid 30944564)
9. Nelson AL, Teal SB. Medical therapies for chronic menorrhagia. Obstet Gynecol Surv. 2007 Apr;62:272-281
10. Hofmann GE, Rao CV, De Leon FD, Toledo AA, Sanfilippo JS. Human endometrial prostaglandin E2 binding sites and their profiles during the menstrual cycle and in pathologic states. Am J Obstet Gynecol 1985 Feb 1;151:369-375
11. Rose PG. Endometrial carcinoma. N Engl J Med 1996 Aug 29;335:640-649
12. Creatsas G, Deligeoroglou E. Polycystic ovarian syndrome in adolescents. Curr Opin Obstet Gynecol 2007 Oct;19:420-426
13. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990 Aug;97:734-739
14. Savaris RF, Braun RD. Menorrhagia and hemoglobin levels. Int J Gynaecol Obstet 2007 Jun;97:199-200.
15. Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002 Oct;100:683-687
16. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005 Jun;43:517-520
17. Mansour D. The role of hormonal and non-hormonal drug therapies in the management of abnormal uterine bleeding. Gynecol Forum 2007;12:19-22.
18. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994 Aug;5:537-542
19. Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995 Summer;11:456-471
20. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970 Oct 24;4:214-216
21. Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995 Nov;102:913-917
22. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000249.
23. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006 Oct;26:673-678 (Pubitemid 44663885)
24. Lin X, Gao ES, Li D, Zhang M, Dou LX, Yuan W. Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women. Acta Obstet Gynecol Scand 2007;86:1126-1129 (Pubitemid 47345792)
25. Vermylen J, Verhaegen-Declercq ML, Fierens F, Verstraete M. A double blind study of the effect of tranexamic acid in essential menorrhagia. Bull Soc R Belge Gynecol Obstet 1968;38:385-390
26. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996 Sep 7;313:579-582 (Pubitemid 26293640)
27. Demers C, Derzko C, David M, Douglas J. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006 Oct;95:75-87.
28. Mohri H. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J Thromb Thrombolysis 2002 Dec;14:255-257 (Pubitemid 37069310)
29. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001 Dec 1;99:238-243
30. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995 May;102:401-406
31. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417-1433 (Pubitemid 36776096)
32. Rybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding: clinical update on safety. Therapeutic Advances 1991;4:1-8.
33. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993 Aug 2;70:238-240
34. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007:CD000400.
35. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991 Mar;164:879-883
36. Davies AJ. Reduction of menstrual blood loss by naproxen in intrauterine contraceptive device users. Int J Gynaecol Obstet 1980 Jan-Feb;17:353-354
37. Gonzalez-Correa JA, Arrebola MM, Martin-Salido E, Munoz-Marin J, de la Cuesta FS, De La Cruz JP. Effects of dexibuprofen on platelet function in humans: comparison with lowdose aspirin. Anesthesiology 2007 Feb;106:218-225
38. Raskin JB. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am J Med 1999 May 31;106:3S-12S.
39. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD001016.
40. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008:CD001016.
41. Hickey M, Higham J, Fraser IS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2007:CD001895.
42. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990 Nov;30:353-356
43. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 Jun;105:592-598 (Pubitemid 28293475)
44. Fournier A, Hill C, Clavel-Chapelon F. Hormone replacement therapy in menopause and risk of breast cancer. Bull Cancer 2003 Oct;90:821-831 (Pubitemid 37487102)
45. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005 Jul;96:95-108. (Pubitemid 41096673)
46. Fabre A, Fournier A, Mesrine S, Desreux J, Gompel A, Boutron-Ruault MC, et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007 Mar 12;96:841-844 (Pubitemid 46376623)
47. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 Feb 20;115:840-845
48. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006:CD003855.
49. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care 2008 Mar;13:17-24. (Pubitemid 351271845)
50. Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual discharge. Obstet Gynecol 1985 Feb;65:194-198 (Pubitemid 15166979)
51. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000 Dec;96:913-920
52. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007;67:1749-1765 (Pubitemid 47263180)
53. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007 Sep;76:182-189 (Pubitemid 47260594)
54. Marshall JK, Hunt RH. Hormonal therapy for bleeding gastro-intestinal mucosal vascular abnormalities: a promising alternative. Eur J Gastroenterol Hepatol 1997 May;9:521-525
55. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding-a double-blind randomized control study. Obstet Gynecol 1982 Mar;59:285-291
56. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril 1978 Apr;29:397-401.
57. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986;5:235-241 (Pubitemid 17190885)
58. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997 Sep;68:426-429
59. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992 Dec;46:575-584
60. Critchley HO. Endometrial morphology and progestogens. Ernst Schering Res Found Workshop 2005:55-88.
61. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990 Aug;97:690-694 (Pubitemid 20263115)
62. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception 2002 May;65:325-328
63. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol 2004 Dec;111:1425-1428
64. Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003 Apr;79:963-969
65. Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998 Apr 11;316:1122-1126
66. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995 Apr;51:231-235
67. Yazbeck C, Omnes S, Vacher-Lavenu MC, Madelenat P. [Levonorgestrel- releasing intrauterine system in the treatment of dysfunctional uterine bleeding: A French multicenter study]. Gynecol Obstet Fertil 2006 Oct;34:906-913
68. Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001 Jun;6:93-101.
69. Dubuisson JB, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002 Aug;66:121-128
70. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001 Jan;108:74-86. (Pubitemid 32102607)
71. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999 Sep;78:716-721
72. Busfield RA, Farquhar CM, Sowter MC, Lethaby A, Sprecher M, Yu Y, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. Br J Obstet Gynaecol 2006 Mar;113:257-263 (Pubitemid 43961741)
73. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007 Mar;75:193-198
74. Milsom I. The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women. Contraception 2007 Jun;75:S152-4.
75. Lethaby AE, Cooke I, Rees M. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005:CD002126.
76. Cameron IT. Dysfunctional uterine bleeding. Baillieres Clin Obstet Gynaecol 1989 Jun;3:315-327
77. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. Br J Obstet Gynaecol 2005 Aug;112:1121-1125 (Pubitemid 41632669)
78. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, et al. Quality of life and cost-effectiveness of levonorgestrel- releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001 Jan 27;357:273-277
79. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, et al. Clinical outcomes and costs with the levonorgestrel- releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year followup. JAMA 2004 Mar 24;291:1456-1463
80. Intrauterine devices and intrauterine systems. Hum Reprod Update 2008 May-Jun;14:197-208.
81. Mansour D. Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007 Dec;21:1007-1021
82. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 2007 Jun;75:S161-6.
83. Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet 2007 Jun;97:190-194 (Pubitemid 46733985)
84. Clegg JP, Guest JF, Hurskainen R. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin 2007 Jul;23:1637-1648
85. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001 Aug;76:304-309
86. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994 Jan;61:70-77
87. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002 Feb;57:120-128
88. Munro MG. Abnormal uterine bleeding in the reproductive years. Part II-medical management. J Am Assoc Gynecol Laparosc 2000 Feb;7:17-35.
89. Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment. J Am Assoc Gynecol Laparosc 2003 Nov;10:505-511 (Pubitemid 38020605)
90. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991 Nov;98:1155-1159
91. Colacurci N, De Placido G, Mollo A, Perino A, Cittadini E. Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol 1995;22:212-219
92. Speroff L GR, Kase N. Clinical Gynecologic Endocrinology and Infertility. 6th ed Philadelphia PA: Lippincott Williams & Wilkins, 1999.
93. Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007:CD001017.
94. Kuppermann M, Varner RE, Summitt RL, Jr., Learman LA, Ireland C, Vittinghoff E, et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA 2004 Mar 24;291:1447-1455
95. Abbott JA, Garry R. The surgical management of menorrhagia. Hum Reprod Update 2002 Jan-Feb;8:68-78.
96. Bourdrez P, Bongers MY, Mol BW. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel- releasing intrauterine device, or hysterectomy. Fertil Steril 2004 Jul;82:160-166, quiz 265.
97. Fu YS, Gambone JC, Berek JS. Pathophysiology and management of endometrial hyperplasia and carcinoma. West J Med 1990 Jul;153:50-61. (Pubitemid 20221835)
98. Driguez P, Jondet M, Becker JF, Le Nestour E, Yaneva H. Traitement de l'hyperplasie de l'endomètre par la promégestone. Actual Reprod Hum 1994;5:6-10.
99. Dargent D. Prise en charge des ménométrorragies dites rebelles : retour sur quelques évidences. Jobgyn 1996;4:383-391
100. Berdah J. Etude multicentrique sur 1974 patientes présentant un syndrome prémenstruel. Gynécologie 1990;41(suppl2):27-33.
101. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997 Sep;90:434-440
102. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003 Dec;91:526-533
103. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003 May;188:1297-1298 (Pubitemid 36589125)
104. Bahamondes L, Ribeiro-Huguet P, de Andrade KC, Leon- Martins O, Petta CA. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand 2003 Jun;82:580-582
105. Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 2003 Dec;91:569-572
106. Agorastos T, Bontis J, Vakiani A, Vavilis D, Constantinidis T. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997 Apr;65:102-114
107. Agorastos T, Vaitsi V, Paschopoulos M, Vakiani A, Zournatzi- Koiou V, Saravelos H, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas 2004 Jun 15;48:125-132
108. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003 Dec;80:1315-1324
109. Fedele L, Bianchi S, Marchini M, Di Nola G. Histological impact of medical therapy-clinical implications. Br J Obstet Gynaecol 1995 Oct;102 Suppl 12:8-11.
110. Jasonni VM, Naldi S, La Marca L, Bulletti C, Ciotti P, Vignudelli A, et al. Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects. Cancer Detect Prev 1986;9:331-335
111. Sedati A, Mariani L, Giovinazzi R, Yacoub M, Atlante G. The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia. Clin Exp Obstet Gynecol 1992;19:161-165
112. Soh E, Sato K. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1990 Sep 1;66:983-988
113. Mais V, Cossu E, Angioni S, Piras B, Floris L, Melis GB. Abnormal uterine bleeding: medical treatment with vaginal danazol and five-year follow-up. J Am Assoc Gynecol Laparosc 2004 Aug;11:340-343 (Pubitemid 39195579)
114. Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, et al. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. Gynecol Obstet Invest 2004;58:42-48 (Pubitemid 39140407)
115. Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis JN. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005 Feb 1;118:239-240 (Pubitemid 40093842)